Ibrutinib resistance in chronic lymphocytic leukemia
New England Journal of Medicine, 2014•Mass Medical Soc
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is active in CLL, but resistance may emerge.
The authors observed the emergence of a CLL clone with a cysteine-to-serine change in
amino acid 481 of the target protein that substantially weakens drug binding and leads to
resistance.
The authors observed the emergence of a CLL clone with a cysteine-to-serine change in
amino acid 481 of the target protein that substantially weakens drug binding and leads to
resistance.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is active in CLL, but resistance may emerge. The authors observed the emergence of a CLL clone with a cysteine-to-serine change in amino acid 481 of the target protein that substantially weakens drug binding and leads to resistance.
The New England Journal Of Medicine